ondansetron has been researched along with Liver Failure, Acute in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Liver Failure, Acute: A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 9.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| " Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients assigned to the shorter modified protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen (adjusted odds ratio 0·26, 97·5% CI 0·13-0·52; p<0·0001), and in 45 of 109 patients who received ondansetron compared with 65 of 108 allocated placebo (0·41, 0·20-0·80; p=0·003)." | 5.19 | Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. ( Bateman, DN; Butcher, I; Cooper, JG; Coyle, J; Dear, JW; Eddleston, M; Gray, A; Lewis, SC; Rodriguez, A; Sandilands, EA; Thanacoody, HK; Thomas, SH; Veiraiah, A; Vliegenthart, AD; Webb, DJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bateman, DN | 1 |
| Dear, JW | 1 |
| Thanacoody, HK | 1 |
| Thomas, SH | 1 |
| Eddleston, M | 1 |
| Sandilands, EA | 1 |
| Coyle, J | 1 |
| Cooper, JG | 1 |
| Rodriguez, A | 1 |
| Butcher, I | 1 |
| Lewis, SC | 1 |
| Vliegenthart, AD | 1 |
| Veiraiah, A | 1 |
| Webb, DJ | 1 |
| Gray, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning[NCT01050270] | Phase 4 | 222 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ondansetron and Liver Failure, Acute
| Article | Year |
|---|---|
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.
Topics: Acetaminophen; Acetylcysteine; Adult; Aged; Alanine Transaminase; Antiemetics; Double-Blind Method; | 2014 |